Seegene Unveils CURECA Potential to Revolutionize PCR Automation for Diagnostics

Seegene's Groundbreaking CURECA System Set to Transform PCR Automation

Seegene Inc., a pioneering force in molecular diagnostics, has recently garnered significant attention following the unveiling of its innovative CURECA system during the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 conference in Vienna, Austria. This conceptual video presentation, showcased from April 11 to 15, created a buzz among an audience of healthcare professionals, as it illustrated CURECA's potential in revolutionizing the PCR diagnostic process through automation.

What is CURECA?

CURECA is designed to streamline the entire PCR diagnostic process, an essential method used to detect genetic material from pathogens. The system's modular architecture allows it to handle various specimen types, such as stool, urine, blood, and sputum. By automating pre-treatment and managing the diagnostic workflows, CURECA promises to enhance laboratory efficiencies while minimizing human error—a common challenge in traditional manual processing.

Young-Seag Baeg, who heads Strategy and Planning at Seegene, noted the system's significant potential: "CURECA's fully automated setup is tailored for integration into labs that require flexible yet rigorous testing processes. It's not just a step forward; it's a leap into the future of diagnostics."

Positive Reception at ESCMID Global 2025

The response from attendees at ESCMID Global 2025 was overwhelmingly positive, with over 2,300 professionals visiting Seegene's booth to view the concept video. Feedback highlighted the efficacy of the automation process, especially in reducing tedious manual steps often associated with specimen preparation. Comments from attendees included expressions of high hopes for the system's capabilities, with many professionals recognizing its potential to free up valuable time for laboratory staff and enhance testing accuracy.

One expert remarked, "The automation of such critical pre-processing stages can drastically improve turnaround times, particularly in urgent diagnostics like sexually transmitted infections. There's a palpable excitement about how this system could transform laboratory operations."

Key Features of CURECA

At the heart of CURECA lies the Customizable Pre-treatment System (CPS). This component not only automates the loading of primary sample tubes but also integrates seamlessly into diverse diagnostic fields. It is designed to address the pressing need for enhanced automation in laboratories grappling with high volumes of samples and intricate workflows.

In conjunction with the CPS, Seegene offers the Primary Sample Aliquot System (PAS). This module bypasses pre-treatment for certain specimens, fostering an even simpler workflow. The configurability of CURECA means that each lab can tailor the system according to its specific operational requirements, embodying a highly adaptable approach in laboratory automation.

The Future of Diagnostic Workflows

Many industry experts at the conference recognized CURECA as not just a product but a pivotal solution in driving forward the speed and quality of diagnostic testing. With its need for less manual input and streamlined operation, it's expected to make a significant impact on the efficiency of diagnostic laboratories worldwide.

The modular nature allows for broader applications, as articulated by Jong-Yoon Chun, Seegene's CEO, "Our goal is to provide innovative solutions that meet evolving lab demands. The global reaction to CURECA confirms a strong need for next-generation diagnostic capabilities."

Conclusion: A New Era in PCR Automation

As laboratories continue facing increasing demands for rapid and accurate diagnostics, systems like CURECA will play a crucial role. The integration of advanced automation technology aims not only to improve testing outcomes but also to democratize access to high-quality diagnostic tools, enabling smaller healthcare facilities to benefit from the same efficiencies.
In summary, CURECA represents a significant paradigm shift in the practice of PCR diagnostics, potentially laying the groundwork for a future of intelligent healthcare automation. As Seegene prepares for a full launch later this year, the excitement surrounding CURECA suggests that it may well change the landscape of molecular diagnostics irrevocably.